Möhlig Matthias, Weickert Martin O, Ghadamgadai Elham, Machlitt Andrea, Pfüller Bettina, Arafat Ayman M, Pfeiffer Andreas F H, Schöfl Christof
Department of Endocrinology, Diabetes and Nutrition, Charité-University Medicine Berlin, Campus Benjamin Franklin, 12200 Berlin, Germany.
Eur J Endocrinol. 2007 Aug;157(2):195-200. doi: 10.1530/EJE-07-0102.
Many polycystic ovary syndrome (PCOS) women suffer from adiposity and insulin resistance (IR), which play an important role in the development and maintenance of PCOS. Adipocyte fatty acid-binding protein (A-FABP) is mainly expressed in adipocytes, and circulating A-FABP has been associated with markers of obesity and IR. Thus, as observed with other adipose tissue derived factors, secreted A-FABP might be involved in the pathogenesis of obesity-associated disorders such as PCOS.
Plasma A-FABP concentrations were measured in 102 non-diabetic PCOS women, and associations with markers of obesity, IR, inflammation, and hyperandrogenism were investigated by correlation and multiple linear regression analyses. The effect of lifestyle intervention on A-FABP was studied in a second cohort of 17 obese PCOS women.
A-FABP correlated with body mass index (BMI; R = 0.694, P < 0.001), dual-energy X-ray-absorptiometry (DEXA) fat mass (R = 0.729, P < 0.001), DEXA lean body mass (R = 0.399, P = 0.001), HOMA %S (R = -0.435, P < 0.001), hsCRP (R = 0.355, P = 0.001), and free testosterone (fT; R = 0.230, P = 0.02). Adjusted for age, smoking, and glucose metabolism the association of A-FABP with HOMA %S was still significant (P < 0.001), whereas the associations with fT (P = 0.09) and hsCRP (P = 0.25) were not. Inclusion of BMI into the model abolished the impact of A-FABP on HOMA %S. In BMI-matched PCOS women (n = 20 pairs), neither HOMA %S (P = 0.3) nor fT (P = 0.6) were different despite different A-FABP levels (P < 0.001), and in 17 obese PCOS women undergoing a lifestyle intervention, changes in IR were not paralleled by changes in A-FABP.
Circulating A-FABP was correlated with markers of obesity, but had no major impact on IR, inflammation, or hyperandrogenemia in PCOS women.
许多多囊卵巢综合征（PCOS）女性存在肥胖和胰岛素抵抗（IR），这在PCOS的发生和维持中起重要作用。脂肪细胞脂肪酸结合蛋白（A-FABP）主要在脂肪细胞中表达，循环中的A-FABP与肥胖和IR标志物相关。因此，与其他脂肪组织衍生因子一样，分泌的A-FABP可能参与肥胖相关疾病如PCOS的发病机制。
测定102例非糖尿病PCOS女性的血浆A-FABP浓度，并通过相关性和多元线性回归分析研究其与肥胖、IR、炎症和高雄激素血症标志物的关系。在另一组17例肥胖PCOS女性中研究生活方式干预对A-FABP的影响。
A-FABP与体重指数（BMI；R = 0.694，P < 0.001）、双能X线吸收法（DEXA）测定的脂肪量（R = 0.729，P < 0.001）、DEXA测定的瘦体重（R = 0.399，P = 0.001）、HOMA %S（R = -0.435，P < 0.001）、高敏C反应蛋白（hsCRP；R = 0.355，P = 0.001）和游离睾酮（fT；R = 0.230，P = 0.02）相关。校正年龄、吸烟和糖代谢后，A-FABP与HOMA %S的关联仍然显著（P < 0.001），而与fT（P = 0.09）和hsCRP（P = 0.25）的关联不显著。将BMI纳入模型后消除了A-FABP对HOMA %S的影响。在BMI匹配的PCOS女性（n = 20对）中，尽管A-FABP水平不同（P < 0.001），但HOMA %S（P = 0.3）和fT（P = 0.6）均无差异，并且在17例接受生活方式干预的肥胖PCOS女性中，IR的变化与A-FABP的变化不平行。
循环中的A-FABP与肥胖标志物相关，但对PCOS女性的IR、炎症或高雄激素血症无重大影响。
